Articles published by IntraBio Inc.

IntraBio Reports Further Detail on Positive Data from Levacetylleucine Pivotal Trial for the Treatment of Ataxia-Telangiectasia

February 11, 2026

From IntraBio Inc.

Via Business Wire

IntraBio Receives European Commission Approval of AQNEURSA® for the Treatment of Niemann-Pick Type C Disease

January 21, 2026

From IntraBio Inc.

Via Business Wire

IntraBio Announces Positive Pivotal Trial Results of Levacetylleucine for the Treatment of Ataxia-Telangiectasia

January 21, 2026

From IntraBio Inc.

Via Business Wire

AQNEURSA® (levacetylleucine) Recommended for EU Approval by the CHMP to Treat Niemann-Pick Disease Type C

July 30, 2025

From IntraBio Inc.

Via Business Wire

IntraBio Inc. Completes Recruitment for IB1001 A-T Pivotal Clinical Trial

July 01, 2025

From IntraBio Inc.

Via Business Wire

IntraBio Announces U.S. FDA Approval of AQNEURSA for the Treatment of Niemann-Pick Disease Type C

September 25, 2024

From IntraBio Inc.

Via Business Wire

IntraBio Reports Further Detail On Positive Data From IB1001 Multinational Clinical Trial For The Treatment of GM2 Gangliosidosis

September 14, 2021

From IntraBio Inc.

Via AccessWire

IntraBio Reports Statistically Significant and Clinically Meaningful Improvements in the Use of IB1001 For Treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease)

August 19, 2021

From IntraBio Inc.

Via AccessWire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.